When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

These include Kisunla in Alzheimer's disease; Ebglyss, an eczema treatment; and ulcerative colitis therapy Omvoh. Further, Eli Lilly has an incredibly deep pipeline. Yes, here too, the company's ...

Other than Mounjaro and Zepbound, Lilly has gained approvals for some other new drugs in the past couple of years across different therapeutic areas like Omvoh, Jaypirca, Ebglyss and Kisunla ...

Successful clinical trials and international approvals, such as for the drug Omvoh for Crohn's disease and Ebglyss for atopic dermatitis, further resulted in positive sentiment. These concerted ...